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Theprionprotein (PrPC) is a conserved glycosylphosphatidyl-
inositol-anchored cell surface protein expressed by neurons and
other cells. Stress-inducible protein 1 (STI1) binds PrPC extra-
cellularly, and this activated signaling complex promotes neu-
ronal differentiation and neuroprotection via the extracellular
signal-regulated kinase 1 and 2 (ERK1/2) and cAMP-dependent
protein kinase 1 (PKA) pathways. However, the mechanism by
which the PrPC-STI1 interaction transduces extracellular sig-
nals to the intracellular environment is unknown. We found
that in hippocampal neurons, STI1-PrPC engagement induces
an increase in intracellular Ca2 levels. This effect was not
detected in PrPC-null neurons or wild-type neurons treated
with anSTI1mutant unable tobindPrPC.Using abest candidate
approach to test for potential channels involved in Ca2 influx
evoked by STI1-PrPC, we found that -bungarotoxin, a specific
inhibitor for 7 nicotinic acetylcholine receptor (7nAChR),
was able to block PrPC-STI1-mediated signaling, neuropro-
tection, and neuritogenesis. Importantly, when 7nAChR
was transfected into HEK 293 cells, it formed a functional
complex with PrPC and allowed reconstitution of signaling by
PrPC-STI1 interaction. These results indicate that STI1 can
interact with the PrPC7nAChR complex to promote signal-
ing and provide a novel potential target for modulation of the
effects of prion protein in neurodegenerative diseases.
Prions are the infectious components of transmissible spon-
giformencephalopathies that can self-perpetuate by imprinting
an anomalous conformation onto a glycosylphosphatidylinosi-
tol-anchored host protein known as the prion protein (PrPC).3
Conversion of PrPC to the protease-resistant prion is thought to
be a major event in prion diseases (1). However, despite the
wealth of knowledge on prions, the roles of PrPC on synaptic
function and neuronal health are still not completely under-
stood. Studies in yeast, mammalian cells, and mouse models
support the hypothesis that PrPC plays a major role in neuro-
protection and neuronal differentiation (for review, see Refs.
1–3).
In humans, the initial cognitive dysfunction observed in
transmissible spongiform encephalopathies is remarkably sim-
ilar to those observed in Alzheimer disease (AD). Therefore,
synaptic failure is likely to play a major role in the cognitive
alterations seen in these neurological disorders (4). For
instance, in AD, the role for A ligands in synaptic dysfunction
has received considerable attention (5, 6). Interestingly, recent
work provided evidence that PrPC functions as a receptor for
A and that this interaction mediates some of the effects of A
oligomers in synaptic plasticity (7) although these results are
controversial at the moment (8, 9). Moreover, PrPC seems to
regulate the -secretase cleavage of amyloid precursor protein,
thereby regulating the production of A (10). In addition,
-secretase regulates the cleavage of PrPC, generating anN-ter-
minal fragment with neuroprotective activity (11, 12).
PrPC also binds to transmembrane proteins such as the
67-kDa laminin receptor (13–15), neuronal cell adhesion mol-
ecule (16, 17), G protein-coupled serotonergic receptors (18),
and low density lipoprotein receptor-related protein 1 (19, 20),
which are able to promote intracellular signaling-mediated
neuronal adhesion and differentiation as well as PrPC internal-
ization. Remarkably, PrPC functions as a receptor or co-recep-
tor for extracellularmatrix proteins such as laminin (21, 22) and
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vitronectin (23), as well as the secreted co-chaperone stress-
inducible protein 1 (STI1) (24). These data suggest that glyco-
sylphosphatidylinositol-anchored PrPC is a potential scaffold
receptor in a multiprotein, cell surface, signaling complex, that
may be the basis for themultiple neuronal functions ascribed to
PrPC (2, 3, 25).
We demonstrated previously that PrPC amino acids 113–128
constitute the STI1 binding site (24). Furthermore, PrPC-STI1
engagement rescues retinal and hippocampal neurons from
staurosporine-induced programmed cell death through activa-
tion of protein kinase A (PKA). Additionally, PrPC-STI1 bind-
ing also induces the differentiation and protein synthesis in
hippocampal neurons via extracellular signal-regulated kinase
1 and 2 (ERK1/2) and phosphoinositide 3-kinase (PI3K)–Akt-
mTOR activation (26, 27). Trafficking of both PrPC and STI1
following binding at the membrane regulates the ERK1/2 path-
way, but does not alter PrPC regulation of PKA signaling (28).
Although several signaling pathways triggered by PrPC have
been identified, little is known regarding how intracellular sig-
naling is activated by PrPC following its interaction with extra-
cellular ligands. In this studywemapped the upstream signaling
events triggered by PrPC-STI1 binding to identify the putative
transmembrane protein responsible for connecting this extra-
cellular complex to the intracellular milieu. Our data show that
hippocampal neuronal signaling induced by PrPC-STI1 is
dependent on calcium influx through the 7 nicotinic acetyl-
choline receptor (7nAChR). These results provide a novel
mechanism by which PrPC transduces extracellular signals,
with implications for PrPC-mediated regulation of synaptic
function and neuronal differentiation.
EXPERIMENTAL PROCEDURES
Reagents—Mouse recombinant STI1 (His6-STI1) and an
STI1 deletion mutant lacking the PrPC binding site
(STI1230–245) were purified as described previously (24).
The mitogen-activated protein kinase MAPK/ERK1/2 (p44/
p42 MAPK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis (2-
aminophenylthio) butadiene (U0126) was purchased from Pro-
mega. The PKA inhibitor KT5720, phosphodiesterase inhibitor
isobutylmethylxanthine, and 4-6-diamidino-2-phenylindole
(DAPI) were purchased from Calbiochem. The PKA activator
(forskolin) was purchased from LC Laboratories (Woburn,
MA). The L-type calcium channel blocker (nifedipine), Ca2-
ATPase inhibitor (thapsigargin, THG), FLAG beads, FLAG
peptide, and anti-FLAG antibodies were obtained from Sigma-
Aldrich. The Q-type Ca2 channel blocker (-conotoxin
MCVII) was purchased from Latoxan (Valence, France). The
store-operated calcium channel blocker (SKF-96365) and
7nAChR blocker (-bungarotoxin, Bgt) were purchased
fromTocris Biociences (Ellisville,MO). Fluo-3 AM, neurobasal
medium, Opti-MEM, Hanks’ buffered saline solution, and
Lipofectamine were obtained from Invitrogen. Anti-phospho-
ERK1/2 and anti-total ERK1/2 antibodies were purchased from
Cell Signaling Technology (Beverly, MA), and peroxidase-cou-
pled goat anti-rabbit secondary antibody and enhanced chemi-
luminescence (ECL) solution were obtained from GE Health-
care. Complete Protease InhibitorMixturewas purchased from
Roche Applied Science. The PKA assay system kit was pur-
chased from Upstate Biotechnology. Anti-cleaved caspase-3,
Alexa Fluor 488 anti-rabbit antibodies, and Alexa Fluor 647
Bgt were purchased from Molecular Probes. Immu-Mount
was purchased from Thermo Scientific (Waltham, MA). The
monoclonal antibodies 3F4 and 6H4 against PrPC were
acquired from Abcam (Cambridge, MA) and Prionics (Schlie-
ren, Switzerland).
Animals and Primary Neuronal Cultures—PrPC-null mice
(Prnp0/0), descendants of the ZrchI line, were provided by Dr.
Charles Weissmann (Scripps Florida). Wild-type animals were
generated by crossing F1 descendants from 129/SV and
C57BL/6J matings. All studies were conducted in accordance
with National Institutes of Health guidelines for the care and
use of animals andwith animal protocols approved by the Insti-
tutional Animal Care and Use Committee.
Primary cultures of hippocampal neurons from embryonic
day 17 (E17) wild-type (Prnp/) or PrPC-null mice (Prnp0/0)
were obtained as previously described (26) and plated onto
poly-L-lysine (5 g/ml)-coated coverslips (35 mm) for 4 days.
Ca2 Signaling and Data Analysis—Neurons and HEK 293
cells were loaded with 10 M intracellular Ca2 indicator
Fluo-3 AM for 30 min at 37 °C in the presence of neurobasal
medium or Opti-MEM supplemented with 2 mM CaCl2. Cells
were washed three times with Hanks’ buffered saline solution
and resuspended in Krebs buffer (124 mM NaCl, 4 mM KCl, 25
mMHepes, 1.2 mMMgSO4, 10mM glucose) supplemented with
2 mM CaCl2. Ca2-free experiments were performed in Krebs
bufferwithoutCaCl2 plus 1mMEGTA.Cellswere preincubated
(30 min) in the presence of 25 M SKF-96365, voltage-gated
calcium channel (VGCC) inhibitors (1M-conotoxinMCVII
plus 50 M nifedipine) or 1 nM Bgt. Cells were treated with
recombinant STI1 (1 M for neurons and 2 M for HEK 293),
which mimics the effects of STI1 secreted from astrocytes (28,
29). HEK 293 cells were also pretreated with monoclonal anti-
bodies against PrPC (6H4 and 3F4 both at 10g/ml) followed by
recombinant STI1 (2 M). In addition, recombinant STI1
deleted of the PrPC binding site, STI1230–245 (2M) (26)was
used in control experiments, and treatment with THG (1 M)
was performed to estimate calcium responses. Data acquisition
was performed by confocal microscope using either a Bio-Rad
Radiance 2100/Nikon (TE2000U) or a Zeiss LSM 510 (Zeiss,
Toronto,ON)with excitation at 488 nm (argon laser) and emis-
sion collected with bandpass filter at 522–535 nm. The fluores-
cence was normalized as F1/F0 (F1, maximal fluorescence after
drug addition and F0, basal fluorescence before drug addition).
Software-based analysis (WCIF ImageJ (National Institutes of
Health)) allowed quantification of fluorescence imaging in
selected cells as a function of time. Experiments were carried
out with at least three different cell cultures, and 40–50 cells
were monitored in each experiment. Traces represent typical
single-cell responses.
ERK1/2 Activity—Primary hippocampal neurons (1  106
cells) from Prnp/mice were plated on dishes pretreated with
poly-L-lysine and stimulated with STI1 (350 nM) for 1 min (26)
in the presence or absence of 2 mM CaCl2. Some cells were also
preincubated with 1 nM Bgt for 30 min prior to STI1 treat-
ment. Cells were rinsed with ice-cold phosphate-buffered
saline (PBS) and lysed in Laemmli buffer. Cell extracts were
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subjected to SDS-PAGE (10%), and proteins were transferred
onto nitrocellulose membranes. The membranes were blocked
(5%milk, 0.1%Tween 20 inTris-buffered saline) for 1 h at room
temperature, incubated with anti-phospho-ERK1/2 or anti-to-
tal ERK1/2 antibodies (1:2,000) overnight at 4 °C, followed by
incubation with peroxidase-coupled, goat anti-rabbit second-
ary antibody (1:2,000) for 1 h at room temperature. Reactions
were developed using ECL solution, and the bands obtained
after x-ray film exposure to the membranes were analyzed by
densitometric scanning and quantified using ImageJ software.
Alternatively, in some experiments, a CCD-based system was
used (Alpha Innotech). ERK1/2 band densities activity was
quantified as a relative value representing the ratio between
phospho-ERK1/2 and total ERK1/2 for each sample. Results
represent five independent experiments for neurons and three
separate experiments for HEK 293 cells.
PKA Activity—Primary hippocampal neurons (1 106 cells)
were preincubated with 100M isobutylmethylxanthine for 1 h
at 37 °C, followed by incubation with 1M STI1 in the presence
or absence of extracellular CaCl2 (2 mM) or forskolin (10 M)
for 20 min at 37 °C as a positive PKA signaling control. Cells
were washed with cold PBS and homogenized in ice-cold
extraction buffer (150 mM NaCl, 20 mM MgCl2, 1% Triton
X-100, and 25 mM Tris-HCl, pH 7.4), including Complete Pro-
tease Inhibitor mixture. Cellular debris was removed by centri-
fugation at 6,000 g for 10 min. PKA activity was determined
by [-32P]ATP incorporation to a PKA-specific substrate pro-
vided by the PKA assay system kit.
Neuritogenesis Assays—Primary hippocampal neurons (4 
104) from wild-type (Prnp/) mice were treated with STI1
(350 nM) and incubated for 24 h at 37 °C. Neuritogenesis medi-
ated by STI1was evaluated after preincubationwith 10 nMBgt
for 30 min. The cells were fixed with 4% paraformaldehyde and
0.12 M sucrose in PBS, pH 7.4, for 20 min at room temperature,
washed three times with PBS, and stained with hematoxylin.
Morphometric analyses were performed using ImageJ soft-
ware and the Neuron J plug in. The parameters analyzed were
percentage of cells with neurites and percentage of neurons
with neurites longer than 30 m, which represents three or
more times the average cell body. Approximately 200 cells were
analyzed per sample.
Cell Death Assay—Primary hippocampal cultures (7  104
cells) were treated with STI1 (1.2 M) for 1 h, followed by stau-
rosporine (50 nM) treatment for 16 h as described previously
(26). Alternatively, Bgt (10 nM) was added to the cultures 30
min prior to incubation with STI1. Cells were then fixed with
4% paraformaldehyde and 0.12 M sucrose in PBS, pH 7.4, for 20
min, and immunofluorescence reactions were performed to
detect cleaved caspase-3. Briefly, cells were permeabilized and
blocked with PBS/0.2% Triton X-100 plus 5% BSA for 1 h and
subsequently incubated with anti-cleaved caspase-3 primary
antibody (1:200) diluted in PBS/0.2%TritonX-100 plus 1%BSA
for 2 h. After rinsing with PBS, cells were incubated with Alexa
Fluor 488 anti-rabbit antibody and DAPI for 1 h. Immunola-
beled cells were imaged with a BX61 Olympus Fluorescence
microscope. Cell death induced by staurosporine was
addressed by counting the percentage of cleaved caspase-3-
positive cells. Results represent three independent experi-
ments; at least 300 cells total were counted per condition.
DNA Constructs—The cDNA encoding the human
7nAChR subunit was cloned fromahumanuniversalQUICK-
Clone cDNA library (Clontech) using the forward primer,
5-CGACAGCCGAGACGTGGA-3 and reverse primer,
5-CCGATGGTACGGATGT GC-3, designed to prime from
the untranslated regions of the sequence (NCBI Reference
Sequence: NM_000746). A forward primer, introducing a
BamHI restriction site and minimal Kozak sequence (5-GCC-
GGGATCCGCCACCATGCGCTGCTCGCCGGGA-3) to
the N terminus, and a reverse primer, introducing an XbaI
restriction site, FLAG epitope tag sequence (DYKDDDDK) and
stop codon (5-CGGCTCTAGATTACTTGTCGTCGTCGT-
CCTTATAGTCCGCAAAGTTTTGGACACGGCC-3) to the
C terminus, were used to clone the FLAG-7nAChR sequence
into the pcDNA3.1 expression vector (Invitrogen).
The cDNA for human resistance to inhibitors of cholinester-
ase 3 homolog (Caenorhabditis elegans) (hRIC3; NCBI Refer-
ence Sequence: NM_024557.2) was purchased from OriGene
(Rockville, MD). A forward primer, introducing a KpnI
restriction site and minimal Kozak sequence (5-GGCGGTA-
CCGCCACCATGGCGTACTCCACAGTGCAGAGAGTC-
3) to the N terminus, and a reverse primer, introducing a NotI
restriction site, HA epitope tag sequence (YPYDVPDYA) and
stop codon (5-GCGGCCGCCAACTCGCATAATCCCA-
CATCATACGGATACTCTAAACCCTGGGGGTTACGCT-
TCCT-3) to the C terminus, were used to clone theHA-hRIC3
sequence into the pcDNA5/FRT expression vector
(Invitrogen).
HEK293Cell Transfection—Cellswere transfectedwith plas-
mids expressing FLAG-7nAChR with or without those
expressing HA-hRIC 3 (1:1), using either a modified calcium
phosphate method (30, 31) or Lipofectamine. To test transfec-
tion efficiency, cells transferred to coverslips were incubated
with 500 nM Alexa Fluor 647-Bgt in Hanks’ buffered saline
solution containing 0.1% BSA for 1 h on ice. For confocal
microscopy analyses, cells were washed with Hanks’ buffered
saline solution, fixed with PLP (0.2% periodate, 1.4% lysine, 2%
paraformaldehyde), and coverslips were mounted onto glass
microscope slides with Immu-Mount. Images are single z-sec-
tions captured by an LSM 510Meta laser scanning microscope
with excitation at 633 nm (HeNe laser) and a 650–710-nm
bandpass emission filter.
Co-immunoprecipitation Assays—HEK 293 cells were trans-
fected with plasmids expressing mouse PrPC bearing the 3F4
epitope (26) and FLAG-7nAChR with or without HA-RIC 3
(1:1) cDNAs, as described above. Two days after transfection,
2–3 106 cells were lysed in 250ml of 50mMTris-HCl, pH 7.5,
150mMNaCl, and 1%TritonX-100, plus protease inhibitors for
15 min on ice, followed by two sonication pulses. Protein
extracts (800 g) were incubated with 20 l of FLAG beads for
16 h at 4 °C. Beads were washed three times with wash buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, pH 7.4, and proteins
were eluted by incubating the beads with 15 g of FLAG pep-
tide (in 100l of 50mMTris-HCl, pH7.4, and 150mMNaCl) for
10 min at room temperature. One quarter of the eluate was
resolved by 4–12% SDS-PAGE, followed by immunoblotting
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with anti-FLAG antibodies. The remaining eluate was resolved
with a second 4–12% SDS-PAGE, followed by immunoblotting
with anti-PrPC (3F4). These experiments were repeated four
times.
Statistical Analysis—The statistical analyses were performed
using GraphPad Prism 4. Results are represented as means 
S.E., and the total number of experiments is specified in each
figure legend. Data were compared by one-way ANOVA and
Newman-Keuls post test.
RESULTS
PrPC-STI1 Interaction Increases Intracellular Ca2—We
demonstrated previously that PrPC-STI1 engagement resulted
in ERK1/2 phosphorylation and PKA activation, which in turn
promoted neuritogenesis and neuroprotection, respectively
(26). Ca2 signaling is an early event upstream of both PKA and
ERK1/2 activation (32, 33). In addition, PrPC has consistently
been shown tomodulate Ca2 signaling (34–36). Therefore, to
determine whether STI1 interaction with PrPC affects intracel-
lular Ca2 levels, we performed Ca2 imaging experiments on
cultured hippocampal neurons using Fluo-3 AM. STI1 treat-
ment promoted intracellular Ca2 increases in neurons derived
from Prnp/mice (Fig. 1,A andD), but no effect was observed
in neurons from Prnp0/0 mice (Fig. 1, B andD). However, treat-
ment with THG, a blocker of the endoplasmic reticulumCa2-
ATPase, mobilized the release of intracellular Ca2 stores (Fig.
1B), suggesting that these stores were available in Prnp0/0 neu-
rons. Consistent with these observations, intracellular Ca2
levels remained unchanged in hippocampal neurons treated
with a mutant STI1 missing the PrPC binding site (STI1230–
245) (Fig. 1, C and D). Interestingly, when Ca2 was removed
from the extracellular medium, STI1 had no effect on intracel-
lular Ca2 levels (Fig. 1, A and D). These results suggest that
PrPC-STI1 engagement can activate Ca2 influx.
Ca2 Influx Induced by PrPC-STI1 Interaction Promotes
ERK1/2 and PKA Activation—The effect of PrPC-STI1-medi-
ated Ca2 influx on ERK1/2 and PKA activation was tested in
wild-type neuronal cultures. In the presence of extracellular
Ca2, STI1 treatment increased both PKA and ERK1/2 activa-
tion (Fig. 2). Forskolin, which activates adenylyl cyclase and
increases intracellular levels of cAMP, was used as a positive
control for PKA activation (Fig. 2A). Conversely, no effect was
observed when cells were treated with STI1 in the absence of
FIGURE 1. STI1 interaction with PrPC promotes intracellular Ca2
increase. A and B, Prnp/ (A) or Prnp0/0 (B) hippocampal neurons loaded
with Fluo-3 AMwere treated with STI1 (1M) inmedium supplemented with
(solid lines) or without (dashed line) Ca2. THG-treated Prnp0/0 neurons show
normal levels of intracellular Ca2 stores. C, Prnp/ neurons were treated
with an STI1 deletion mutant, STI1230–245, lacking the PrPC binding site.
D, relative intracellular Ca2 levels in Prnp0/0 (white bars) and Prnp/ (black
bars) neurons treated with STI1 or STI1230–245 in the presence or absence
of CaCl2 are indicated. The results represent the mean  S.E. (error bars) of
four independent experiments, and statistical significance was determined
by one-way ANOVA and Newman-Keuls post test. *, p 0.05 compared with
controls.
FIGURE 2. PKA activation and ERK1/2 phosphorylation are dependent on
PrPC-STI1-induced Ca2 influx. PKA (A) and ERK1/2 (B) activation was
induced by STI1 treatment in Prnp/ hippocampal neurons. Experiments
were performed with or without CaCl2, as indicated. Forskolin-treated cells
were used as positive controls for PKA activation. Relative levels of ERK1/2
activity represent the ratio between phosphorylated ERK1/2 (upper panel)
and total ERK1/2 (lower panel) normalized to the untreated group. The results
represent the mean S.E. (error bars) of four independent experiments, and
statistical significance was determined by one-way ANOVA and Newman-
Keuls post test. *, p 0.05 compared with controls.
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extracellular Ca2 (Fig. 2). Thus, upstream Ca2 signaling is
required for PrPC-STI1-mediated ERK1/2 and PKA activation.
PrPC-STI1 Interaction Induces Ca2 Influx through
7nAChR—The PrPC-STI1 interaction likely induces Ca2
influx via modulation of an unidentified Ca2 channel at the
plasma membrane. Transmembrane Ca2 channels include
VGCCs and several ligand-gated channels. To determine the
Ca2 channel responsible for PrPC-STI1-mediatedCa2 influx,
we used a best candidate approach. To ascertain the role of
VGCCs in this response, we used a VGCC inhibitor mixture
(-conotoxinMCVIIC andnifedipine) targeting themajority of
neuronal Ca2 channels, including Cav2.1, Cav2.2, Cav1.1,
Cav1.2, and Cav1.3. Hippocampal neurons still exhibited Ca2
influx upon STI1 treatment in the presence of VGCC inhibitors
(Fig. 3A), although Ca2 influx due to KCl depolarization was
blunted (data not shown).
To determine which ligand-gated channel might transduce
PrPC-STI1-mediated Ca2 influx, modulators of transient
receptor potential channels and several neurotransmitter
receptors (data not shown) were utilized. One candidate, the
7nAChR, has been shown to activate PKA and ERK1/2 (37)
and to promote neuronal differentiation and survival (38–40).
In the presence of the 7nAChR-specific inhibitor Bgt, the
PrPC-STI1-mediated intracellular Ca2 influx was abolished
(Fig. 3B).Moreover, PKAactivation (Fig. 3C) and ERK1/2 phos-
phorylation (Fig. 3D) were com-
pletely blocked in the presence of
Bgt. These data show that STI1
binding to PrPC induces intracellu-
lar Ca2 influx via modulation of
7nAChR, leading to ERK1/2 and
PKA activation.
To verify whether 7nAChR can
be modulated by PrPC-STI1, we
used HEK 293 cells, which do not
express endogenous 7nAChR, to
reconstitute the expression of these
receptors. HEK293 cells were trans-
fected with plasmid vectors encod-
ing PrPC, 7nAChR, or 7nAChR
and RIC3 a chaperone that is
required for correct assembly of this
receptor at the cell surface (41). The
functional expression of 7nAChR
at the cell surface was confirmed by
binding of fluorescent Bgt only
upon its co-expression with RIC3
(Fig. 4A).
Co-immunoprecipitation experi-
ments using anti-FLAG antibodies
against FLAG-tagged 7nAChR,
followed by immunoblotting using
anti-3F4 antibodies toward 3F4-
tagged mouse PrPC (28) or anti-
FLAG antibodies, demonstrated
that PrPC physically interacts with
7nAChR in these cells (Fig. 4B). To
further test whether heterologous
expression of 7nAChR was able to reconstitute PrPC-STI1-
mediated Ca2 signaling, we performed signaling experiments
inHEK 293 cells.When these cells were transfectedwith empty
vector (Fig. 5A), or with the vector encoding PrPC alone (Fig.
5B), STI1 treatment did not induce an increase in the level of
intracellular Ca2. Similar results were observed in cells trans-
fected onlywith7nAChR (Fig. 5C), likely due to the absence of
RIC3. However, when HEK 293 cells were co-transfected with
vectors encoding 7nAChR, RIC3, and PrPC, STI1 was able to
increase intracellular Ca2 (Fig. 5E). Interestingly, even in cells
transfected only with7nAChR/RIC3, STI1was able to evoke a
Ca2 signal although this effect could be blocked by antibodies
against PrPC (3F4 and 6H4) (Fig. 5D). In addition, STI1 deleted
of the PrPC binding site (STI1230–245) was unable to induce
Ca2 signaling (Fig. 5F). These results indicate that endogenous
levels of PrPC expression in HEK 293 cells are sufficient to pro-
mote Ca2 signaling when 7nAChR is present. These data are
quantified in Fig. 5G.
PrPC-STI1 Interaction Induces PKA and ERK1/2 Activation
through 7nAChR—We also found that STI1 induced both
PKA activation (Fig. 6A) and ERK1/2 phosphorylation (Fig.
6B) in HEK 293 cells transfected with both 7nAChR and
RIC3. Conversely, activation of PKA or ERK1/2 was not
observed upon STI1 treatment when these cells were trans-
FIGURE3.PrPC-STI1 interaction inducesCa2 influx, PKAandERK1/2activation through7nAChR.A and
B, intracellular Ca2 levels in Prnp/ hippocampal neurons were treated with STI1 (1 M) in the presence
(dashed line) or absence (solid line) of VGCC inhibitors (n  3) (A) or in the presence (dashed line) or absence
(solid line) of Bgt, a specific inhibitor of 7nAChR (n  4) (B). C and D, PKA activity (n  3) (C) and ERK1/2
(n 3) phosphorylation (D) weremeasured in Prnp/hippocampal neurons treatedwith STI1 in thepresence
of Bgt, as indicated. Forskolin was used as a positive control for PKA activation. Relative levels of ERK1/2
activity represent the ratio between phosphorylated ERK1/2 (upper panel) and total ERK1/2 (lower panel),
normalized to the untreated group. The results were compared by one-way ANOVA and Newman-Keuls post
test. *, p 0.05 compared with controls.
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fected with empty vector or 7nAChR alone (Fig. 6 and data
not shown).
PrPC-STI1 Interaction Induces Neuroprotection and Neu-
ritogenesis through 7nAChR—To determine whether STI1-
PrPC-mediated neuroprotection and neuritogenesis were
also dependent on 7nAChR, we analyzed activated
caspase-3 levels and neurite outgrowth in hippocampal neu-
rons. In primary neuronal cultures, staurosporine-induced
cell death was blocked by STI1 treatment, and this was
reversed by preincubation with Bgt (Fig. 7A). In addition,
the treatment of hippocampal neurons with Bgt blocked
PrPC-STI1-mediated neuritogenesis, as measured by the
percentage of cells with neurites (Fig. 7B) or the percentage
of cells with neurite length 30 m (Fig. 7C). Taken
together, these data indicate that the PrPC-STI1 interaction
modulates 7nAChR activity, thereby inducing Ca2 influx
and PKA and ERK1/2 activation and ultimately promoting
neuronal protection and differentiation.
DISCUSSION
In this study, we demonstrate that PrPC binding to STI1
increases Ca2 influx in neurons through 7nAChR. These
results provide new insight into the physiological role of PrPC as
well as a novel mechanism by which PrPC transduces extracel-
lular signals.
The PrPC-STI1 interaction has been shown tomodulate neu-
ronal differentiation and survival. Furthermore, these activities
are dependent on activation of PKA, ERK1/2, and PI3K–mTOR
via PrPC (26, 27). STI1 is secreted from astrocytes (29), and its
FIGURE 4. PrPC interacts with 7nAChR. A, HEK 293 cells were transfected
with expression vector lacking insert (vector) or vectors encoding FLAG-
tagged 7nAChR (7) or FLAG-tagged 7nAChR and RIC3 (7/RIC3). Cells
were incubated with Alexa Fluor 647 Bgt and analyzed by confocal micros-
copy. Phase contrast images indicate the field of cells (top panels), and green
fluorescence indicates Alexa Fluor 647 Bgt-labeled cells (bottom panels).
B, HEK 293 cells were transfected with expression vector lacking insert (Vec-
tor) or expression vectors encoding PrPC either alone (PrPC) or co-transfected
with FLAG-tagged 7nAChR and RIC3 (7/RIC3). Immunoprecipitation (IP)
was performed with anti-FLAG antibodies, and proteins from total lysates
(Input) or eluates (IP-FLAG)were immunoblotted (IB)withanti-PrPC (IB-PrPC) or
anti-FLAG (IB-FLAG) antibodies.
FIGURE 5. Expression of 7nAChR rescues PrPC-STI1-mediated Ca2
influx in HEK 293 cells. A–F, HEK 293 cells were treatedwith 2M STI1 alone
(A–CandE), STI1 in thepresenceofPrPC antibodies 6H4or3F4 (D), or 2MSTI1
deleted of the PrPC binding site, STI1230–245 (F). Cells were transfected
with empty vector (n 5) (A), PrPC (n 4) (B), 7nAChR (n 4) (C), 7nAChR
andRIC3 (D) and treatedwith STI1 alone (n 8) or in thepresence of 6H4 (n
4) or 3F4 (n 3), PrPC, 7nAChR, and RIC3 (n 4) (E) or 7nAChR and RIC3
(n  5) (F). Cells were treated with THG, when indicated, to test the level of
intracellular Ca2 stores. G, relative levels of intracellular Ca2 in cells trans-
fected and treated as indicated are shown. The results represent themean
S.E. (error bars) of independent experiments compared by one-way ANOVA
and Newman-Keuls post test. *, p 0.01 compared with controls.
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activity is 100 times higher than recombinant STI1, probably
due to a better folding or posttranslational modifications (28).
The mechanisms associated with STI1 secretion are presently
under investigation, but the protein is likely to use a noncon-
ventional type of secretion due to the absence of a signal peptide
(42). However, it is clear that secreted STI1 binds to PrPC,
potentially acting as a neurotrophic-like factor (25). Interest-
ingly, hippocampal infusion of STI1 or an STI1-derived peptide
(STI1pep230–245), which mimics the PrPC binding site,
increases PrPC-dependent memory consolidation. On the
other hand, antibodies against either STI1 or its peptide 230–
245 were able to impair memory formation (43). These results
indicate that the STI1-PrPC interaction has physiological con-
sequences in vivo.
PrPC appears to act as a receptor or co-receptor for a number
of ligands, including transmembrane, aggregated and soluble
proteins. Therefore, it is important to dissect the mechanisms
bywhich glycosylphosphatidylinositol-anchored PrPC is able to
transduce extracellular signals to the intracellular milieu. Pre-
viously, PrPC has been shown to interact with neuronal cell
adhesion molecule to stimulate Fyn-kinase (17). Furthermore,
PrPC has also been shown to associate with G protein-coupled
serotonergic receptors, interfering with the intensities and/or
dynamics of G protein activation by agonist-bound 5-HT
receptors (18, 44). PrPC also acts as a receptor for A1–42
oligomers to inhibit synaptic plasticity in the form of long term
potentiation (7). In addition, PrPC interacts with the  chain
subunit of the extracellular matrix protein laminin (21). Our
recent data demonstrate that laminin 1 chain interaction with
PrPC triggers neuronal signaling via group I metabotropic glu-
tamate receptors, and regulates intracellular Ca2 levels and
neuritogenesis (62).
STI1 Activates 7nAChR and Ca2-dependent Signaling
Pathways—Our data strongly indicate that STI1 activation of
Ca2 influx is dependent on its engagement with PrPC, as neu-
rons fromPrPC-null mice do not respond to STI1.Moreover, in
FIGURE 6. Expression of 7nAChR in HEK 293 cells rescues PrPC-STI1-in-
duced PKA activity and ERK1/2 phosphorylation. PKA activity (A) and
ERK1/2 phosphorylation (B) in HEK 293 cells transfectedwith empty vector or
co-transfected with expression vectors for 7nAChR and RIC3. Cells were
treatedwith forskolin, STI1, or choline chloride as indicated. Relative levels of
ERK1/2 activity represent the ratio betweenphosphorylated ERK1/2 and total
ERK1/2 (upper panel) in cells treated with STI1 and normalized to cells trans-
fectedwith empty vector. The results represent themean S.E. (error bars) of
three independent experiments compared by one-way ANOVA and New-
man-Keuls post test. *, p 0.01 compared with controls.
FIGURE 7. PrPC-STI1 interaction promotes neuroprotection and neurito-
genesis through 7nAChR. A, Prnp/ hippocampal neurons were treated
with STI1 (30 min) or STI1 and Bgt, followed by staurosporine, as indicated.
Cells were immunolabeled with anti-activated caspase-3, which labels apo-
ptotic cells. Data are represented as the percentage of activated caspase-3-
positive cells. B and C, Prnp/ hippocampal neurons were treated with STI1
alone, or STI1 plus Bgt, as indicated, and neuritogenesis was measured as
the percentage of cells with neurites or with neurites30 m, respectively.
The results represent themean S.E. (error bars) of three independent exper-
iments, compared by one-way ANOVA and Newman-Keuls post test. *, p 
0.01 compared with controls.
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wild-type cultured hippocampal neurons, Ca2 influx fails in
the presence of STI1 lacking the PrPC binding site.
The inhibition of STI1-evoked Ca2 influx, ERK1/2 phos-
phorylation, and PKA activation in Bgt-treated neurons is
consistent with the fact that STI1 can modulate 7nAChR via
PrPC.Moreover, the fact that STI1-mediated signaling is recon-
stituted in transfected HEK 293 cells supports the idea of a
functional interaction between PrPC and7nAChR. Indeed, we
detected a physical interaction between PrPC and 7nAChR.
The mechanisms by which STI1 modulates 7nAChR activ-
ity through its interaction with PrPC are unknown. For
instance, it is unclear whether STI1 and PrPC act together to
activate 7nAChR, or whether they modulate 7nAChR sensi-
tivity to agonists. It should be noted that choline, a proposed
7nAChR agonist (45), is normally found in the extracellular
milieu, albeit at a concentration too low to activate 7nAChR
(45). Hence, it is possible that STI1-PrPC engagement modu-
lates the response of7nAChR to extracellular choline. Further
experiments using electrophysiology techniques will be neces-
sary to refine possible mechanisms.
Remarkably, the effects of STI1 on neuritogenesis and pro-
tection against staurosporine-induced neuronal cell deathwere
also completely blocked by Bgt. Extensive studies have shown
that 7nAChR regulates many brain functions (45). These
receptors are formed by homomeric assembly of five subunits
and are preferentially permeable to Ca2 (45). Furthermore,
7nAChR activation has been shown to be neuroprotective
(46–48) and to regulate learning and memory (for review, see
Ref. 49) in an ERK1/2- and PKA-dependent manner (50).
The 7nAChR has also been implicated in AD (51–54), as
expression of these receptors is either decreased or increased in
AD brains (55, 56) and animalmodels of AD (57). Furthermore,
there is evidence that 7nAChR interacts with A1–42 olig-
omers (58, 59). Moreover, recent experiments involving
7nAChR knock-out mice crossed with transgenic mice
expressing mutated amyloid precursor protein suggest that the
synaptic toxicity observed in the latter may be due in part to
7nAChR (60). On the other hand, experiments using a sepa-
rate transgenic mouse model for AD indicate that these recep-
tors may be protective at early ages. Interestingly, drugs that
prevent binding of A1–42 to7nAChR seem to be beneficial in
a model of AD (58). Hence, it seems that STI1 binding to PrPC
can hijack one of the key signaling pathways related to AD and
learning and memory. Therefore, it is possible that STI1 mod-
ulation of a complex containing PrPC and 7nAChR may play
an important role in AD.
Little is known regarding the role of nAChRs in prion dis-
eases. Recent data demonstrated that PrPC is co-localized with
the4 subunit of nAChR in the brain and gastrointestinal tract.
However, infection experiments using the Rocky Mountain
Laboratory prion strain in 4nAChR knock-out mice demon-
strated that these animals presented with the same disease
incubation period when compared with controls (61).
In summary, we show that STI1 interaction with PrPC can
modulate Ca2 influx via7nAChR, thereby promoting neuro-
nal survival and differentiation (Fig. 8). Future experiments will
need to define the mechanisms involved in PrPCmodulation of
7nAChR as well as the pathophysiological roles of this new
signaling complex in prion diseases and AD.
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